Effects of different types of hormone replacement therapy on mammographic density

Maturitas

Volumn 40, Issue 2, 2001, Pages 159-164

  Colacurci, Nicola ^a,b   Fornaro, Felice ^a   De Franciscis, Pasquale ^a   Palermo, Mario ^a   Del Vecchio, Walter ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

^b NONE   (Italy)

Author keywords

Breast; Hormone replacement therapy; Mammography; Postmenopause

Indexed keywords

ESTRADIOL; FOLLITROPIN; NOMEGESTROL ACETATE; TIBOLONE;

ADULT; ARTICLE; BODY MASS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DENSITY; DRUG EFFECT; ESTRADIOL BLOOD LEVEL; FEMALE; FOLLITROPIN BLOOD LEVEL; FOLLOW UP; HORMONE SUBSTITUTION; HUMAN; HYSTERECTOMY; MAJOR CLINICAL STUDY; MAMMARY GLAND; MAMMOGRAPHY; MENARCHE; OVARIECTOMY; PARENCHYMA; PARITY; POSTMENOPAUSE; PRIMIGRAVIDA;

ADMINISTRATION, CUTANEOUS; BREAST; ESTRADIOL; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; MAMMOGRAPHY; MEGESTROL; MIDDLE AGED; NORPREGNADIENES; NORPREGNENES; POSTMENOPAUSE; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 0035976495     PISSN: 03785122     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0378-5122(01)00232-8     Document Type: Article

References (34)

1. Oestrogen therapy and the menopausal syndrome
2. Long-term estrogen replacement therapy prevents bone loss and fractures
3. Postmenopausal estrogen therapy and cardiovascular disease
4. Breast cancer and hormone replacement therapy: Collaborative reanalysis of data from 51 epidemiological studies of 52705 women with breast cancer and 108411 women without breast cancer
5. The lifetime risk of developing breast cancer
6. The benefits and risks of mammographic screening for breast cancer
7. Case-control study of factors associated with failure to detect breast cancer by mammography
8. Effect of mammographic breast density on breast cancer screening performance: A study in Nijmegen, the Netherlands
9. Mammographic parenchymal patterns and quantitative evaluation of mammographic densities: A case-control study
10. Mammographic and ultrasonographic study of changes in the breast related to HRT
11. Enlarging occult fibroadenomas
12. Hormonal replacement therapy: Mammographic manifestation
13. Pain and increased mammographic density in women receiving hormone replacement therapy: A prospective study
14. Effect of postmenopausal hormone replacement therapy on mammographic density and parenchymal pattern
15. Effect of estrogen and estrogen-progestin replacement regimens on mammographic breast parenchymal density
16. Mammographic changes in postmenopausal women on hormone replacement therapy
17. Mammographic breast density during hormone replacement therapy: Differences according to treatment
18. Hormone replacement therapy with estrogen or estrogen plus medroxyprogesterone acetate is associated with increased epithelial proliferation in the normal postmenopausal breast
19. A correlative morphologic study of the human breast and endothelium in the menstrual cycle
20. Tibolone and climacteric symptoms
21. Tibolone as an alternative to estrogen for the prevention of postmenopausal osteoporosis in selected postmenopausal women
22. Effects of tibolone on the breast
23. Effect of estrogen replacement therapy on the specificity and sensitivity of screening mammography
24. The effect of hormone replacement therapy on recall rate in the National Health Service Breast Screening Programme
25. Effect of hormone replacement therapy on cancer detection by mammography
26. Hormone replacement therapy and accuracy of mammographic screening
27. Effects of estrogen and estrogen-progestin on mammographic parenchymal density
28. Breast density as a predictor of mammographic detection: Comparison of interval- and screen-detected cancers
29. The effect of hormone replacement therapy on the sensitivity of screening mammograms
30. Effect of hormone replacement therapy on breast cancer risk: Estrogen versus estrogen plus progestin
31. Hormone replacement therapy as treatment of breast cancer - A phase II study of Org OD14 (tibolone)
32. Tibolone actions on normal and breast cancer cells
33. Effects of Org OD14 (Livial) and its metabolites on 17 beta-hydroxysteroid dehydrogenase activity in hormone-dependent MCF-7 and T-47D breast cancer cells
34. Effect of Org OD14 (Livial) and its metabolites on human estrogen sulphotransferase activity in the hormone-dependent MCF-7 and T-47D, and hormone-independent MDA-MB-231, breast cancer cell lines